Future directions in the field of prostate cancer management include RP for advanced and oligometastatic disease in the context of combined modality therapy51 and the role of new immunotherapeutic agents, such as programmed cell death protein (PD-1) and PD-L1 inhibitors52,53. This evidence concerns the gene CD274 and prostate carcinoma.